WeLab Barcelona has reached an agreement with Spirify Pharma for a research collaboration on characterization of Spirify’s proprietary analogs of hydroxynorketamine.

Spirify Pharma is a preclinical-stage biotech company developing novel small molecule NCEs that are targeted to provide orally available non-addictive alternatives to ketamine and target large market segments with high unmet medical need, like neuropathic pain, migraine, depression, and neurodegenerative diseases.

Link to the press release by Spirify Pharma: https://lnkd.in/ecRif7xk